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Abstract Biphasic insulin aspart 30 (BIAsp 30) includes 30% soluble rapid-acting
insulin aspart (IAsp) along with an intermediate-acting 70% protaminated
IAsp that provides coverage of prandial and basal insulin in a single injection.
As BIAsp 30 has been available internationally for 10 years, this review
provides a comprehensive overview of the discovery of BIAsp 30, its pharm-
acokinetic and pharmacodynamic profile, safety and efficacy outcomes from
the clinical trial programme, ‘real-life’ clinical insights provided by observa-
tional study data, and cost effectiveness and quality-of-life information. These
studies have demonstrated that BIAsp 30 once or twice daily is an appro-
priate option for insulin initiation. BIAsp 30 also provides a switch option in
patients on biphasic human insulin (BHI). Switching fromBHI to BIAsp 30 is
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associated with improved postprandial glucose (PPG) and reduced nocturnal
and major hypoglycaemia, although daytime hypoglycaemia is higher with
BIAsp 30. Intensification of BIAsp 30 can be achieved by increasing the
number of daily doses up to three times daily with meals. Therefore, BIAsp 30
provides an intensification option for individuals who are not achieving
control with basal insulin and would prefer the simplicity of a single biphasic
insulin instead of progressing to a basal-bolus approach. BIAsp 30 has a
simple dose-titration algorithm, which enables patients to effectively self-
titrate their insulin dose. Cost-effectiveness analyses have demonstrated that
BIAsp 30 is cost effective or dominant compared with BHI 30 or insulin
glargine in a number of healthcare settings. In conclusion, BIAsp 30 offers a
simple and flexible option for insulin initiation and intensification that pro-
vides coverage of both fasting and prandial glucose.
1. Introduction
Biphasic insulin aspart 30 (BIAsp 30) was laun-
ched on the international market in 2002, and over
the past 10 years it has been used by millions of
patients to provide effective control of their dia-
betes. Given the fact that BIAsp 30 has been used in
patients for 10 years, there is a wealth of informa-
tion available to document its efficacy and safety.
An important goal of diabetes treatment is to
achieve target glycated haemoglobin (HbA1c) as
early in the course of the disease as possible and
to maintain HbA1c as the diabetes progresses.
Landmark trials such as DCCT (Diabetes Control
and Complications Trial) and the UKPDS (United
Kingdom Prospective Diabetes Study) have dem-
onstrated the importance of achieving glycaemic
targets in order to reduce the long-term risk of
diabetes-related complications.[1,2] For example,
in the UKPDS, newly diagnosed patients were
randomized to conventional therapy primarily
with diet, or intensive therapy with a sulphonylurea
or metformin plus insulin.[2] Over a 10-year in-
tervention period there was an 11% reduction in
mean HbA1c in the intensive-therapy group com-
pared with the conventional group (7.0% and 7.9%,
respectively).[2] The improvement in glycaemic
control in the intensively treated group resulted
in a 25% reduction in the risk of microvascular
endpoints (p< 0.001) and a 12% lower risk for any
diabetes-related endpoint (p = 0.029). In a 10-year
follow-up, patients returned to normal clinical
care and no attempt was made to continue the
interventions. Despite the fact that HbA1c dif-
ference was lost after 1 year of the interventions
finishing, a ‘legacy effect’ was observed in the
intensively treated group, with risk reductions in
microvascular disease, myocardial infarction,
any diabetes-related endpoint and death by any
cause, which persisted at the 10-year follow-up.[3]
Both fasting plasma glucose (FPG) and post-
prandial glucose (PPG) contribute to overall HbA1c
control and, at lower HbA1c values, the relative
contribution of PPG becomes more important.[4]
It is therefore logical, in order to achieve gly-
caemic targets, that diabetes therapies addressing
both FPG and PPG should be initiated from as
early as possible in the disease process.[5] The need
to target both FPG and PPG is supported by evi-
dence suggesting that uncontrolled PPG is asso-
ciated with an increased risk of cardiovascular
disease, which is an important cause of morbidity
and the major cause of death in patients with
diabetes.[6,7]
While achieving andmaintaining good glycaemic
control is important to minimize long-term dia-
betic complications, the risk of hypoglycaemia
increases with more intensive diabetes therapy,
which can have a major impact on the health and
well-being of patients. Epidemiological associa-
tions between hypoglycaemia and cardiovascular
morbidity and mortality have been reported, al-
though proof of causality has not been demon-
strated.[8] In addition, the health economic benefits
of improving HbA1c, measured in quality-adjusted
life-years, is counteracted in those patients who
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experience adverse outcomes such as hypoglycaemia
and weight gain.[9] Even non-serious hypoglycaemic
events have an important impact on patients, and
can result in 1–2 days of lost productivity a
month.[10] Therefore, the balance between achiev-
ing appropriate glycaemic control and avoiding
excessive adverse outcomes needs to be found.
This review will provide a comprehensive
summary of BIAsp 30, including information on
drug development, pharmacokinetics and pharma-
codynamics, clinical trials, observational studies,
database studies, meta-analyses, and health eco-
nomic and quality-of-life research.
1.1 Literature Search
A literature search carried out on 6 June 2011
using the terms ‘biphasic insulin aspart’ identified
162 English-language articles, 52 of which were
excluded (25 because BIAsp 30 was not the focus
of the article or similar results were reported in
other references included in this review and 27
because they were review articles). A separate
search was carried out for the ‘Discovery of the
Molecule’ section, using the terms ‘Brange J’ and
‘insulin’, ‘phenol B28 Pro Asp’ and ‘bioactivity
insulin analogues’, ‘receptor’ and ‘in vivo glu-
cose’. These searches identified 44 publications,
of which six were directly relevant to the devel-
opment of BIAsp 30. Therefore, a total of 116
articles were included in this review.
2. Discovery of Biphasic Insulin Aspart
(BIAsp)
The amino acid structure of the human insulin
monomer consists of an A-chain with 21 amino
acids and a B-chain of 30 amino acids linked
covalently by two interchain disulphide bonds.[11]
The A-chain includes two antiparallel alpha-helices
while the B-chain includes one alpha-helix and a
beta-strand (reviewed by Brange and Langkjoer[11]).
Insulin has a tendency to self-associate so the
monomer exists only at concentrations <10-7 M.
At higher concentrations in the pH range 4–8, the
molecule dimerises and in the presence of zinc
ions the three dimers come together to form
hexamers at concentrations >10-5 M.[11]
Human soluble insulin exists in a hexameric
form in pharmaceutical preparations, which delays
its absorption into the bloodstream following
subcutaneous injection as the size of the hexamer
impedes diffusion through the capillary mem-
brane into the bloodstream. The dissociation into
the dimer and monomer forms, which are more
readily absorbed into the bloodstream, requires the
molar concentrationof insulin to decrease to<10-7M
and the absence of zinc ions.[12] These conditions
are achieved as the insulin slowly diffuses away
from the injection depot (figure 1).[12]
The delay in absorption into the bloodstream
means that patients injecting human soluble in-








Fig. 1. Dissociation of insulin hexamers following subcutaneous injection. Reproduced from Brange et al.,[12] with permission from the
American Diabetes Association. ª 1990 American Diabetes Association.
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their insulin at least 30 minutes before a meal.
This can be inconvenient and is an issue for those
patients with erratic eating habits. In consequence,
many patients inject their human soluble insulin
much closer to mealtimes, which means that they
do not adequately control their PPG excursions and
may be exposed to a greater risk of hypoglycaemia.
Therefore, there was a need to develop a more rap-
idly absorbed insulin to address these issues.
2.1 Development of Insulin Aspart
Insulin aspart (IAsp) is a biosynthetically mod-
ified analogue of human insulin, in which the only
change is the replacement of a single proline
amino acid at position 28 in the insulin B-chain
with an aspartic acid residue (figure 2).[12] The
B28 position was one of the sites chosen for amino
acid substitution because it is involved in the
formation of dimers but lies outside the receptor-
binding region.[13] Substitution of proline with
aspartic acid at B28 impairs dimerisation through
a charge-repulsion effect in the vicinity of the dimer-
forming site, which disrupts the normal van der
Waals interaction between the B28 proline and
B23 glycine (figure S1 in the Supplemental Dig-
ital Content [SDC], available from URL: http://
links.adisonline.com/DGZ/A12).[13] This means
that IAsp is essentially monomeric at pharmaco-
logical concentrations, allowing faster absorption
into the bloodstream.[13] The biological activity
of IAsp is not affected by the substitution at the
B28 position as this area of the molecule is not
involved in receptor binding.[14]
2.2 Formulation of BIAsp 30
With the discovery of neutral protamine Ha-
gedorn (NPH)-like crystals of IAsp,[15] it became
possible to develop a biphasic formulation of
IAsp. BIAsp 30 includes a mixture of 30% soluble
rapid-acting IAsp, along with 70% intermediate-
acting crystallised protamine-complexed IAsp.
BIAsp 50 (50% soluble and 50% protaminated
IAsp) and BIAsp 70 (70% soluble IAsp and 30%
protaminated IAsp) are also available for patients
who require more prandial insulin to provide ef-
fective glycaemic control; however, this review
focuses on BIAsp 30. When administered with








































Fig. 2. Insulin aspart differs from human insulin by the single amino-acid substitution of a proline by an aspartic acid residue at B28.
Reproduced from Brange et al.,[12] with permission from the American Diabetes Association. ª 1990 American Diabetes Association.
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coverage for prandial glucose excursions, while
the intermediate-acting protaminated IAsp crys-
tals provide coverage of basal glucose, respectively.
Protaminated IAsp was preferred to NPH human
insulin becausemixtures of IAsp and protaminated
human insulin underwent exchange during ex-
tended contact, whereas this is avoided using
mixtures of IAsp and protaminated IAsp.[16] In
addition, IAsp retained rapid-acting activity in
mixture with protaminated IAsp.[16]
3. Pharmacokinetics and
Pharmacodynamics of BIAsp 30
In healthy non-diabetic individuals, basal- and
meal-related insulin secretion maintains blood
glucose concentrations within the normal range of
approximately 4–8mmol/L (72–144mg/dL). In in-
dividuals with type 2 diabetes mellitus, insulin resis-
tance and the progressive deterioration of beta-cell
dysfunction impair blood glucose control. In those
individuals who require exogenous insulin, BIAsp 30
offers a pharmacokinetic profile that is closer to
normal physiological insulin secretion than both
biphasic human insulin (BHI 30) and basal insulin.
3.1 BIAsp 30 vs Biphasic Human Insulin (BHI)-30
The pharmacokinetic and pharmacodynamic
profile of BIAsp 30 facilitates more convenient
dosing than BHI 30. In a randomized, double-
blind, two-way, single-dose crossover study of 24
healthy individuals, BIAsp 30 demonstrated faster
absorption and higher peak concentration than
BHI 30 (figure 3a).[17] A euglycaemic clamp study
in 24 healthy subjects demonstrated an earlier and
more pronounced glucose-lowering effect and a
similar duration of action of the basal component
of BIAsp 30 than BHI 30 (figure 3b).[16]
The earlier and more pronounced onset of in-
sulin action with BIAsp 30 means it can be dosed
immediately before or following a meal, in con-
trast to BHI 30, which should be administered at
least 30 minutes before a meal. In 93 patients
aged ‡65 years, postprandial dosing with BIAsp 30
(up to 20 minutes following a meal) offered
similar blood glucose control and no significant
difference in hypoglycaemia compared with pre-
prandial dosing (within 5 minutes before the
meal).[18] BIAsp 30 injected immediately before a
meal provided superior postprandial serum glucose
control compared with BHI 30 injected 15 minutes
before or immediately before the meal. BIAsp 30
injected after the meal provided comparable PPG
control to BHI 30 injected 15 minutes before or
immediately before the meal.[19]
In addition to allowingmore convenient dosing,
there is evidence that BIAsp 30 may also reduce
patient exposure to nocturnal low blood glucose
versus BHI 30. Patients treated with BIAsp 30 ex-
perienced significantly fewer nocturnal episodes
(<3.5mmol/L [<63mg/dL]) per subject per week
than those treated with BHI 30 (1.2 vs 1.6, respect-
ively; p< 0.011) and spent less time at night with low
blood glucose (figure S2 in the SDC).[20]
3.2 BIAsp 30 vs Biphasic Insulin Lispro
An open-labelled, randomized, single-dose,
three-way crossover study examined the pharm-
acokinetic and pharmacodynamic characteristics
of BIAsp 30, biphasic insulin lispro 25/75 and
BHI 30 in 61 individuals with type 2 diabetes
already being treated with insulin.[21] Patients
visited the study centre on three separate days
following an overnight fast. Between visits there
was a 5-day washout period. Current oral and
intermediate or long-acting insulin medication
was discontinued 24 hours before the visit. Pre-
injection blood glucose target levels of 6–10mmol/L
were achieved using a night-time injection of short-
acting insulin. Individuals received a single sub-
cutaneous injection of 0.4 units/kg BIAsp 30,
biphasic insulin lispro 25/75 and BHI 30; follow-
ing which they consumed a standard breakfast.
BIAsp 30 was associated with 17% and 10% lower
serum glucose excursion between 0–5 hours post-
breakfast compared to BHI 30 (p < 0.001) and
biphasic insulin lispro 25/75 (p< 0.05), respectively.
The time to maximum serum glucose was shorter
for BIAsp 30 (75 minutes) than for BHI 30
(88 minutes) or biphasic insulin lispro 25/75
(87 minutes). Measures of insulin pharmaco-
kinetics such as area under the concentration
curve (AUC0–5h), maximum plasma drug con-
centration (Cmax) and time to Cmax (tmax) were
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significantly better for BIAsp 30 versus BHI 30
but not significantly different for BIAsp 30 and
biphasic insulin lispro 25/75.
3.3 BIAsp 30 vs Insulin Glargine
As would be expected, twice-daily dosing of
BIAsp 30 resulted in two distinct peaks of plasma
insulin compared with insulin glargine’s flatter
insulin profile (figure 4).[22] Cmax was achieved
approximately 2–3 hours after BIAsp 30 injec-
tion, compared with a plateau of plasma insulin
between 6 and 16 hours after insulin glargine in-
jection. The overall area under the plasma insulin
profile (AUC0–24h) was 28% (p = 0.001) higher for
BIAsp 30 than insulin glargine, and the glucose-
lowering response (AUC0–24h) for BIAsp 30 was
34% greater than for insulin glargine (p= 0.037).[22]
3.4 BIAsp 30 Three Times Daily vs Basal-Bolus
Therapy
In a 24-hour glucose clamp study, in which
blood glucose was kept at a constant 5.0mmol/L
Dose = 0.3 U/kg
n = 24
















































Fig. 3. Pharmacokinetics and pharmacodynamics of biphasic insulin aspart 30 and biphasic human insulin 30. (a) Serum insulin con-
centration (reproduced from Jacobsen et al.,[17] with kind permission from Springer Science+Business Media). (b) Insulin action (reproduced
fromWeyer et al.,[16] with permission from the American Diabetes Association.ª 1997 American Diabetes Association).BHI = biphasic human
insulin; BIAsp = biphasic insulin aspart; * p <0.0001.
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by intravenous glucose infusion, BIAsp 30 three
times daily showed a similar pharmacodynamic
profile (measured by the glucose infusion rate) to
basal-bolus therapy with once-daily insulin glargine
and three-times daily prandial insulin glulisine
in a crossover study in 24 individuals with type 2
diabetes (figure S3 in the SDC).[23] The authors
observed that the greater glucose-lowering effect
of BIAsp 30 in the evening compared with insulin
glargine plus glulisine would require careful titra-
tion of the evening dose in order to avoid an in-
creased risk of nocturnal hypoglycaemia.
3.5 Special Populations
The pharmacokinetics of BIAsp 30 have not
been investigated in elderly patients, those with
renal or hepatic impairment, or in children or
adolescents.[24] Although renal or hepatic im-
pairment did not demonstrate any clinically rel-
evant effects on the pharmacokinetics of IAsp.[25]
The pharmacokinetic and pharmacodynamic
properties of soluble IAsp have been investigated
in children (6–12 years) and adolescents (13–17
years) with type 1 diabetes. Insulin aspart was
rapidly absorbed in both age groups, with similar
tmax as in adults. However, Cmax differed between
the age groups, stressing the importance of the
individual titration of IAsp.[24] The US FDA
classifies BIAsp 30 as pregnancy category B, re-
flecting the fact that while clinical studies are
limited, animal studies of IAsp have demonstra-
ted no adverse effects on spontaneous reproduc-
tion or abnormalities in fetal development at
clinically relevant doses.[26]
In an exploratory post hoc subanalysis of the
INITIATEplus observational trial in previously
insulin-naive patients with type 2 diabetes, self-
titrated BIAsp 30 was found to be well tolerated
and effective in both those aged >65 years and
those aged £65 years.[27] Patients aged >65 years
had greater HbA1c and FPG reductions (p< 0.05).
Major and minor hypoglycaemia rates were £0.5
episodes per patient-year in both age groups.
4. Safety and Efficacy of BIAsp 30
4.1 Meta-Analysis
Two meta-analyses have compared the safety
and efficacy of premix insulin analogues, such as
BIAsp 30, with long-acting and BHI regimens
in type 2 diabetes.[28,29] In comparison with the
long-acting insulin analogues insulin glargine and
insulin detemir, BIAsp 30 was more effective at
lowering PPG (figure 5a)[28,30-32] andHbA1c (pooled
mean difference 0.48%; 95% CI -0.61, -0.34;
p< 0.001), with similar reductions in FPG (pooled
BIAsp 30
Insulin glargine






















Fig. 4. Comparison of plasma insulin profiles of twice-daily biphasic insulin aspart 30 and once-daily insulin glargine. Reproduced from
Hermansen et al.,[21] with kind permission from Springer Science+Business Media. ª 2006 Springer. BIAsp = biphasic insulin aspart.
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mean difference = 6.4mg/dL; 95% CI -1.5, 14.2;
p= 0.11).[28] The use of BIAsp 30 was associated
with a higher incidence of hypoglycaemia (odds
ratio [OR] for minor hypoglycaemia = 2.8; 95%
CI 1.4, 5.4; p = 0.003) and more weight gain
(pooled mean difference 2.5 kg; 95% CI 1.6, 3.4;
p< 0.001).[28]
Biphasic insulin analogues and BHI appear
to be similarly effective in lowering FPG. How-
ever, BIAsp 30 was reported to be slightly less
effective than BHI in lowering FPG (pooled
mean difference = 8.3mg/dL; 95% CI 0.16, 16.5;
p= 0.04) but was more effective in lowering PPG
(figure 5b),[28,33-35] with similar changes in body-
weight.[28] In comparison with BHI 30, BIAsp 30
was associated with significantly lower rates
of nocturnal (relative risk [RR] = 0.50; 95% CI
0.38, 0.67; p < 0.01) and major hypoglycaemia
(figure 6),[22,29,34,37] but the rate of daytime hypo-
glycaemia was 24% higher with BIAsp 30 (RR
= 1.24; 95% CI 1.08, 1.43; p< 0.01).[29]
4.2 BIAsp 30 vs BHI or Biphasic Insulin Lispro 25
4.2.1 Type 2 Diabetes
In type 2 diabetes, BIAsp 30 was associated
with similar or improved HbA1c control compared
with BHI. A number of studies reported signif-
icantly improved PPG with BIAsp 30, which is
a finding confirmed by the meta-analysis from
Qayyum et al.[28] One study identified a significant
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Fig. 5. Meta-analyses of post-treatment differences in postprandial glucose (mg/dL) between insulin aspart 30/70 and (a) long-acting insulin
analogues[30-32] and (b) biphasic human insulin.[33-35] Reproduced from Qayyum et al.[28]
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was confirmed by the Davidson et al.[29] meta-
analysis, which reported significant benefits for
BIAsp 30 in terms of major and nocturnal hypo-
glycaemia. A summary of the trials comparing
BIAsp 30 and BHI 30 is presented in table I.[33,38-43]
A 12-week multicentre, multinational, open-
label two-period crossover trial compared BIAsp 30
and biphasic insulin lispro 25/75 in 137 in-
dividuals with type 2 diabetes.[44] Both treatments
resulted in similar HbA1c reductions, self-monitored
blood glucose levels were comparable; adverse
events and hypoglycaemia rates (0.69 vs 0.62 epi-
sodes permonth with BIAsp 30 and biphasic insulin
lispro 25/75; p = 0.292) were also similar between
treatments.[44] Based on these data, the authors
concluded that the efficacy and safety profiles of the
two biphasic insulin analogues were comparable.
4.2.2 Type 1 Diabetes
A randomized parallel-group trial looking into
the differences between BIAsp 30 (three times daily
plus NPH at bedtime) and BHI 30 (BHI 30 at
breakfast, soluble insulin at lunch and dinner,
NPH at bedtime) in 167 adolescent patients with
type 1 diabetes found comparable effects on HbA1c
(adjustedmeanHbA1c 9.39% and 9.30% at 16weeks
in the BIAsp 30 and BHI 30 groups, respectively)
and similar rates of hypoglycaemia with the two
treatments.[45] A trial has examined BIAsp 30 com-
pared with BHI 30 in a mixed population of
patients with type 1 or type 2 diabetes, but the
results in the subgroup of patients with type 1
diabetes were not reported separately.[36]
4.3 BIAsp 30 vs Basal Insulin
4.3.1 Type 2 Diabetes
Studies demonstrated comparable or superior
HbA1c control, superior PPG control, a greater
(although overall low) risk of nocturnal hypo-
glycaemia and greater weight gain with BIAsp 30
than with basal insulin (table II).[32,46-48]
4.3.2 BIAsp 30 vs Basal-Bolus Insulin in Type 1Diabetes
One small, open-label, crossover study of 23
patients with type 1 diabetes demonstrated that
BIAsp 30 three times daily plus NPH insulin at

























Test of heterogeneity: I-squared statistic = 0% 
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Fig. 6. Meta-analysis of major hypoglycaemia in patients with type 2 diabetes mellitus treated with biphasic insulin aspart 30 or biphasic
human insulin 30.[21,28,33,35] Reproduced from Davidson et al.,[29] with permission from Elsevier. ª 2009 Elsevier. BHI =biphasic human
insulin; BIAsp = biphasic insulin aspart.
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HbA1c than basal-bolus treatment with human
insulin over 12 weeks (BIAsp 30 vs human insu-
lin: 8.6% vs 8.3%; p < 0.013).[49] Glycaemic con-
trol was comparable in those patients on BIAsp 30
three times daily without NPH compared with
basal-bolus treatment.
4.4 BIAsp 30 for Insulin Initiation
Type 2 diabetes is a progressive disease, typi-
cally managed in a stepwise fashion, with oral
antidiabetic drugs (OADs) introduced once diet
and lifestyle changes have been made. Continuing
decline of beta-cell function means that the initial
choice of OAD (typically metformin) frequently
proves unable to provide adequate glycaemic con-
trol, so treatment intensification is required. In
most people with type 2 diabetes, treatment will
eventually include insulin, either as a first step
after failure of OADmonotherapy or after various
OAD combination therapies have been employed.
In addition to the need to re-establish glycaemic
control with the introduction of insulin therapy in
type 2 diabetes, considerations typically include a
desire to minimize the practical burden of therapy
for the patient, who may be moving to an inject-
able therapy for the first time, and to avoid side
effects of insulin therapy such as hypoglycaemia
and weight gain, which might reduce the accept-
ability of insulin therapy for the patient.
A number of studies have shown that BIAsp 30
is an appropriate option for insulin-naive patients
Table I. Biphasic insulin aspart 30 compared with biphasic human insulin in type 2 diabetes
Study Study details Study endpoint summary
Boehm et al.,[38] 2004 Comparator: BHI 30
Design: ran, controlled, multinational trial over
24mo, BIAsp 30 bid vs BHI 30 bid
Pts: pts with T2DM (n = 125)
No significant difference in mean HbA1c levels between
groups (p= 0.89)





Design: multicentre, ran, open-label, parallel trial
over 24wk, BIAsp 30 tid vs BHI 30 bid
Pts: pts with T2DM (n = 177)
Mean difference in HbA1c levels 0.08% (p= 0.64)
Decreased 7-point BG levels with BIAsp 30 vs BHI 30
after lunch (p= 0.029), before dinner (p= 0.006) and after
dinner (p =0.002)
Schmoelzer et al.,[39] 2005 Comparator: BHI 30
Design: pro, open-label, ran, crossover study,
BIAsp 30 od vs BHI 30 od
Pts: 12 subjects already on premix insulin
Significant reduction in PPG with BIAsp 30 (p= 0.007)
Significant reduction in postprandial hyperlipidaemia




Design: 3mo, single-centre comparative study,
BHI 30 bid vs BIAsp 30 bid
Pts: obese, insulin-naive pts with T2DM (n =50)
on MET
Improved HbA1c reduction with BIAsp 30 +MET
(p< 0.05)
PPG also lower with BIAsp 30 (p <0.05)
No significant differences in number of hypoglycaemic
episodes
Fakhoury et al.,[41] 2010 Comparator: BHI 30
Design: ret study analysing data collected from pts
with T2DM initiated on BHI 30 or BIAsp 30
Pts: pts with T2DM initiated on BHI 30 (n= 632)
or BIAsp 30 (n = 762)
Lower dose of BIAsp 30 required to reach similar HbA1c
levels (p <0.001)
Temizel et al.,[42] 2010 Comparator: BHI 30
Design: trial comparing effects of BIAsp 30 bid or
biphasic insulin lispro 25 vsBHI 30 bid onweight gain
Pts: pts with T2DM (n=140)
No significant differences in weight change between tx
groups (mean 2.1 and 2.3 kg at 12mo with BIAsp 30/
biphasic insulin lispro 25 vs BHI 30)
Ohira et al.,[43] 2011 Comparator: BHI 30
Design: pts were switched to BIAsp 30 bid and
observed for 3mo
Pts: 26 pts with T2DM (HbA1c >6.5%) already
receiving BHI 30 bid
Mobility of LDL fraction decreased significantly with
BIAsp 30 (p< 0.005)
CAVI also decreased with BIAsp 30 (p <0.005)
BG = blood glucose; BHI = biphasic human insulin; BIAsp = biphasic insulin aspart; bid = twice daily; CAVI = cardio-ankle vascular index;
HbA1c=glycated haemoglobin; LDL= low-density lipoprotein; MET=metformin; od= once daily; PPG=postprandial glucose; pro=prospective;
pt(s)= patient(s); ran= randomized; ret= retrospective; tid= three times daily; T2DM= type 2 diabetes mellitus; tx= treatment.
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with type 2 diabetes. In this patient population,
BIAsp 30 offers comparable or improved glycaemic
control compared with BHI 30, insulin glargine,
NPH insulin or OADs along with low rates of
hypoglycaemic episodes.[31,33,35,50-68] Key trials are
summarized in table III.
Raskin et al.[32] compared twice-daily BIAsp 30
with insulin glargine when initiating insulin in
233 insulin-naive patients with type 2 diabetes.
After 24 weeks of insulin treatment, patients re-
ceiving twice-daily BIAsp 30 had lower HbA1c
levels than those receiving insulin glargine (6.91%
vs 7.41%, respectively; p < 0.01) and had experi-
enced a greater HbA1c reduction from baseline
(2.79% vs 2.36%, respectively; p < 0.01). A greater
proportion of BIAsp 30-treated patients reached
target HbA1c levels of £6.5% or 7.0% than those
receiving insulin glargine (p = 0.036 and p < 0.01,
respectively). However, minor hypoglycemia was
more frequent with BIAsp 30 than with insulin
glargine (3.4 and 0.7 episodes per year, respect-
ively; p< 0.05). Weight gain and daily insulin
dose at study end were also higher with BIAsp 30
than with glargine (weight gain 5.4 vs 3.5 kg;
p < 0.01; insulin dose 78.5 and 51.3 units per day,
respectively).
In a double-blind study by Christiansen et al.,[54]
157 of 403 patients included were insulin-naive,
and patients in this group receiving BIAsp 30 twice
daily experienced amean 0.76% reduction inHbA1c
levels over 16 weeks. Although the change in HbA1c
and the incidence of hypoglycaemia were similar
in insulin-naive patients receiving BIAsp 30 twice
daily and NPH insulin twice daily, control of
PPG was significantly better with BIAsp 30. In
the study population as a whole, mean PPG in-
crement over three main meals was significantly
lower with BIAsp 30 twice daily than with NPH
insulin twice daily (0.69mmol/L [12.4mg/dL]
difference between groups; p< 0.001). Reductions
in FPG levels were similar for the two insulin regi-
mens, but prandial glucose increments were lower
with BIAsp 30 than with NPH insulin (5.4mmol/L
vs 7.2mmol/L [97.2 vs 129.6]; p< 0.05).
Table II. Biphasic insulin aspart 30 compared with basal insulin in type 2 diabetes




Design: 28wk, ran, parallel-group trial of BIAsp 30
bid and GLA od
Pts: 209 insulin-naive pts with T2DM previously
on OADs
Lower HbA1c with BIAsp 30 (p< 0.01)
More pts on BIAsp 30 reached target HbA1c levels (p <0.001)




Design: multinational, ran, open-label, parallel-
group trial comparing BIAsp 30 tid vs qid basal-
bolus therapy with NPH and IAsp over 16wk
Pts: 394 pts with T2DM on od or bid insulin regimen
Glycaemic control with BIAsp 30 is non-inferior to IAsp +NPH




Design: 26wk, open-label, ran, parallel-group,
multinational, treat-to-target trial comparing
efficacy and safety of BIAsp 30 od vs GLA od
Pts: 433 insulin-naive pts with T2DM
Reductions in HbA1c of -1.41 for BIAsp 30 and -1.25
for GLA (p =0.029)
Lower plasma glucose levels with BIAsp 30 post-dinner (p= 0.04)
and bedtime (p =0.003)
Risk of nocturnal hypoglycaemia higher with BIAsp 30 (p =0.003)




Design: 24wk, open-label, parallel-group trial of
BIAsp 30 bid and GLA od
Pts: 229 pts with T2DM not maintaining efficient
glycaemic control with GLA +MET + secretagogues
Reductions in HbA1c similar between treatments (p= 0.66)
27.3% and 22.0% of pts achieved target HbA1c on BIAsp 30 and
GLA, respectively (p =0.39)
Final insulin dose was higher for BIAsp 30 than GLA
(1.19 and 0.63U/kg, respectively)
Final minor hypoglycaemia was higher with BIAsp 30 vs GLA
(6.5 vs 3.4 events/pt y; p< 0.05)
Weight change was higher for BIAsp 30 (p< 0.001)
BIAsp=biphasic insulin aspart; bid= twice daily; GLA= insulin glargine; HbA1c= glycated haemoglobin; IAsp= insulin aspart; MET=metformin;
NPH= neutral protamine Hagedorn; OAD=oral antidiabetic drug; od= once daily; pt(s)= patient(s); qid= four-times daily; ran= randomized;
tid= three-times daily; T2DM= type 2 diabetes mellitus.
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Kann et al.[31] compared BIAsp 30 twice daily
plus metformin with a regimen of insulin glargine
plus glimepiride in 255 insulin-naive patients with
type 2 diabetes. In this 26-week study, patients
receiving the BIAsp 30 regimen achieved an HbA1c
reduction of 1.6%, reaching a mean level of 7.5%;
the reduction with BIAsp 30 was significantly
greater than with the insulin glargine regimen
(0.5% difference between groups; p< 0.001). PPG
control was again significantly better with BIAsp 30
(mean prandial glucose increment 1.4mmol/L
[25.2mg/dL]) thanwith insulin glargine (2.2mmol/L
[39.6mg/dL]; p < 0.001). The superior glycaemic
control with the BIAsp 30 regimen was reflected
in a higher incidence of minor hypoglycaemia
(20% vs 9% of patients; p = 0.012), but major
hypoglycaemia was very rare in both groups.
Initiation of insulin with BIAsp 30 as an alter-
native to OAD intensification with a thiazolidi-
nedione was explored in two studies by Raz and
colleagues.[64,65] In a 6-week pilot study, patients
poorly controlled on glibenclamide monotherapy
were randomized either to BIAsp 30 plus rosigli-
tazone or to glibenclamide plus rosiglitazone (i.e.
the addition of a thiazolidinedione to their exist-
ing OAD regimen).[64] Mean daily blood glucose
level was reduced to a greater extent with the
BIAsp 30 regimen than with the thiazolidinedio-
Table III. Key trials of BIAsp 30 in insulin-naive patients




Design: 28wk, ran, parallel-group trial of BIAsp 30 bid and
GLA od
Pts: pts with T2DM inadequately controlled on MET – other
OADs (n = 233)
Mean HbA1c was lower with BIAsp 30 bid than GLA od
More BIAsp 30 subjects reached target HbA1c levels
than with GLA





Design: multicentre, ran, controlled, double-blind,
parallel-group trial of BIAsp 30 bid and NPH bid
Pts: T2DM inadequately controlled on OADs or NPH
(n= 403)
Mean prandial glucose increment was significantly less
with BIAsp 30 bid than with NPH bid
Risk of hypoglycaemia was not significantly different
between tx groups
Kann et al.,[31] 2006 Comparator: GLA +GLIM
Design: 26wk, ran, open-label, parallel-group trial of
BIAsp 30 bid+MET vs GLA +GLIM od
Pts: insulin-naive pts with T2DM (n =255)
HbA1c was significantly lower with BIAsp 30 bid +MET
than GLA od +GLIM
Risk of major hypoglycaemia was similar between
groups, but minor events were more frequent with
BIAsp 30+MET
Raz et al.,[64] 2003 Comparator: ROS +GLIB
Design: 6 wk, multicentre, open-label, parallel-group trial of
BIAsp 30 bid+ROS vs ROS +GLIB
Pts: pts with T2DM inadequately controlled onGLIB (n= 49)
Significant difference in change in mean daily BG
between tx
HbA1c decreased in both tx groups, but the difference
between groups was not significant
Changes in fasting BG were not significant between
groups
Raz et al.,[65] 2005 Comparator: GLIB +PIO
Design: 18wk, international, multicentre, ran, open-label,
parallel-group trial of bid BIAsp 30+PIO or BIAsp 30 bid
vs GLIB +PIO
Pts: pts with T2DM inadequately controlled on a
sulphonylurea (n =281)
At end of trial, BIAsp 30 +PIO was superior to
GLIB +PIO on almost all measures of BG
Significantly lower prandial BG increment for
BIAsp 30+PIO vs GLIB +PIO
Kilo et al.,[35] 2003 Comparator: BHI 30 +MET and or NPH
Design: open-label, ran, parallel-group, multicentre trial of
BIAsp 30 od +MET vs BHI 30 od or NPH od, both with MET
Pts: pts with T2DM inadequately controlled on
MET – sulphonylurea (n= 140)
No significant difference in reduction of HbA1c between
tx groups
Rate of hypoglycaemia was low and did not differ
between tx groups
BG = blood glucose; BHI = biphasic human insulin; BIAsp = biphasic insulin aspart; bid = twice daily; GLA = insulin glargine; GLIB =
glibenclamide; GLIM =glimepiride; HbA1c= glycated haemoglobin; MET =metformin; NPH = neutral protamine Hagedorn; OAD = oral
antidiabetic drug; od = once daily; PIO = pioglitazone; pt(s) = patient(s); ran= randomized; ROS = rosiglitazone; T2DM = type 2 diabetes
mellitus; tx = treatment.
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ne/glimepiride regimen (reductions of 3.8mmol/L
and 2.1mmol/L [68.4 and 37.8mg/dL], respectively;
p= 0.01). Modest reductions of HbA1c were ob-
served in the BIAsp 30 plus rosiglitazone group
and the OAD combination group (0.7% and 0.2%,
respectively), but fructosamine levels were reduced
to a greater extent with the BIAsp 30 regimen
(difference between groups 42.8mmol/L; p= 0.02).
A further, 18-week study in 281 patients com-
pared BIAsp 30 monotherapy and a combination
of BIAsp 30 and pioglitazone with a pioglitazo-
ne–glibenclamide regimen in patients previously
treated with a sulphonylurea.[65] After 18 weeks,
HbA1c levels were significantly lower with BIAsp 30
plus pioglitazone than with glimepiride plus
pioglitazone (difference between groups 0.64%;
p= 0.005), and were also lower than with BIAsp 30
monotherapy (difference 0.6%; p= 0.008). Mean
three-meal prandial glucose increment was lower
with BIAsp 30 plus pioglitazone than with gliben-
clamide plus pioglitazone (difference 0.78mmol/L
[14.8mg/dL]; p= 0.012).
Initiation of insulin as an alternative to con-
tinuing to optimize OAD regimens was also stud-
ied using BIAsp 30 by Bebakar et al.[53] in 191
Western Pacific patients with type 2 diabetes.
Reduction in HbA1c after 26 weeks was signif-
icantly greater with once-daily BIAsp 30 (1.24%;
p< 0.01) and twice-daily BIAsp 30 (1.34%;
p< 0.005) than with the optimized OAD reg-
imen (0.67%). Similar findings were reported by
Raskin et al.,[69] comparing introduction of BIAsp
30 with optimization of an OAD regimen in 200
patients treated withmetformin plus pioglitazone.
At the end of the study, 76% of subjects treated
with BIAsp 30 reached the HbA1c goal of <7.0%,
as compared with 24% treated with OADs only.
Twice-daily BIAsp 30 as a first insulin therapy
in Japanese patients was examined in a 6-month
study comparing this regimen with IAsp three
times daily with NPH insulin as necessary.[50,57]
Overall, the two regimens gave similar reductions
in HbA1c, an effect that was maintained indepen-
dently of body mass index (BMI), age or diabetes
duration.[50]
In addition to trials using twice-daily BIAsp 30,
Kilo et al.[35] studied the use of once-daily in-
sulin initiation in a comparison of BIAsp 30,
BHI 30 and NPH insulin. In patients in poor
glycaemic control at baseline (meanHbA1c 9.5%),
once-daily BIAsp 30 plus metformin reducedHbA1c
by 1.3% over 12 weeks. Similar reductions were
achieved with the other insulins. Although final
HbA1c levels remained above target in many pa-
tients, these data indicate that starting insulin
therapy with once-daily biphasic insulin can achieve
useful improvements in control. Similar results
were reported in a 26-week, open-labelled, ran-
domized, parallel-group, treat-to-target trial of
480 insulin-naive subjects randomized to either
BIAsp 30 before dinner or insulin glargine at bed-
time, plusmetformin andglimepiride in both arms.[47]
Estimated mean reduction in HbA1c from base-
line to end of treatment was -1.41% with BIAsp 30
and -1.25% with insulin glargine (p = 0.029). At
the end of treatment, mean HbA1c was similar in
both groups (7.1% and 7.3% for BIAsp 30 and
insulin glargine, respectively). The RR of minor
nocturnal hypoglycaemia was higher with BIAsp 30
than with insulin glargine (1.1 vs 0.5 episodes
per year; p = 0.003) but overall hypoglycaemia
was low in both groups (table II).[47] A third study
that examined once-daily BIAsp 30 versus insulin
glargine in an Asian population also reported
similar results in terms of a small but statistically
significant difference in HbA1c lowering (-0.36%
difference between groups; p = 0.015), a non-
significantly higher rate of minor and daytime
hypoglycaemia with BIAsp 30, no difference in
nocturnal hypoglycaemia, low rates of serious ad-
verse events, low rates of major hypoglycaemic
episodes and similar mean bodyweight increase in
both groups.[59] In addition, Yang et al.[67,68] ex-
plored BIAsp 30 three times daily as a starting
insulin in Chinese patients with type 2 diabetes.
In this population, three daily BIAsp 30 injections
provided better PPG control after lunch and din-
ner, and greater HbA1c reductions over 24 weeks
than twice-daily BIAsp 30 (values reached 7.01%
vs 6.68%; p< 0.01 for change from baseline).
4.5 Intensifying BIAsp 30 Therapy
The ability to start insulin therapy with a single
daily dose of BIAsp 30 opens the possibility of a
stepwise approach to initiation and intensifica-
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tion, in which an initial once-daily regimen is
supplemented by a second and potentially a third
BIAsp 30 injection as necessary to allow individuals
to reach target HbA1c levels. In one such study,
Garber et al.[70] examined 100 patients with type 2
diabetes. Patients, 72% of whom were insulin-
naive and treated with OADs and the remainder
receiving basal insulin plus OADs, were initially
treated with a single daily dose of BIAsp 30 (with
discontinuation of basal insulin where appro-
priate).[70] Patients self-titrated their BIAsp 30
dose every 3 or 4 days to achieve pre-breakfast
FPG of 80–110mg/dL (4.4–6.1mmol/L). After
16 weeks, 21% of patients had achieved an HbA1c
level of £6.5% and were considered to have com-
pleted the study. Of the remaining patients, 68
individuals entered the second phase of the study,
in which a second daily BIAsp 30 dose was added.
After a further 16 weeks, 25 subjects still did not
have an HbA1c of £6.5%; these patients then re-
ceived a third daily BIAsp 30 dose for the final
16-week period. Overall, this strategy – starting
with a single daily BIAsp 30 dose and adding a
second and third as necessary to achieve HbA1c
target – allowed 60% of subjects to achieve HbA1c
£6.5% and 77% to reach HbA1c £7.0%. Although
minor hypoglycaemia was relatively frequent,
there were no episodes of major hypoglycaemia
and no association between the rate of minor
hypoglycaemia and the number of daily BIAsp 30
injections.
A similar strategy has been applied in other
populations, including Japanese patients with type 2
diabetes.[71,72] In the study by Hosoi et al.,[71] a
high baseline HbA1c level (9.6%) was reflected in
a lower proportion of patients reaching target
HbA1c (51% to £7.0%) than in the study by
Garber et al.[70] Similarly, Yoshioka et al.[72] re-
ported a 49% achievement rate to HbA1c £7.0%
in a population with baseline HbA1c of 8.9%.
4.6 BIAsp 30 vs Exenatide
Two studies comparing BIAsp 30 and twice-
daily exenatide were identified.[63,73] Bergenstal
et al.[73] demonstrated that treatment with once-
daily BIAsp 30 and twice-daily BIAsp 30 in com-
bination with metformin gave superior glycaemic
control to that of exenatide. Both twice-daily and
once-daily BIAsp 30 produced statistically and
clinically significantly greater reductions of HbA1c
from baseline than exenatide (2.76%, 2.34% and
1.75% for twice-daily BIAsp 30, once-daily BIAsp
and exenatide groups, respectively; p< 0.001).
This is in contrast to the Nauck et al.[63] study,
where glycaemic control achieved with twice-daily
exenatide was demonstrated to be non-inferior
to that with twice-daily BIAsp 30. However, a
commentary by Home[74] identified that, while
an optimal dose of exenatide was utilized in the
trial (10 mg daily), insulin dose adjustment was
left to the investigator and at 52 weeks the pre-
mix insulin dose was only 24U/day, well below
doses normally encountered in clinical practice.
It is therefore possible that the results reported
by Nauck et al.[63] reflect suboptimal insulin
dosing.
4.7 Guidance on Dose Titration and Insulin
Intensification
Titration of BIAsp 30 is based on the lowest
pre-meal glucose value over the preceding 3 days
and the dose should be titrated weekly (table S1
in the SDC).[24] For those patients on twice-daily
dosing, titration of the breakfast dose should be
based on the lowest pre-dinner glucose and the
titration of the dinner dose should be based on
the lowest pre-breakfast glucose value. The do-
sage should not be increased if any hypoglycaemic
events are reported within the 3 days. The dose
adjustments are shown in table S1 in the SDC.
A consensus statement covering the intensifica-
tion of basal insulin to BIAsp 30, and the in-
tensification of once-daily or twice-daily BIAsp 30
to twice- or three-times daily BIAsp 30, is avail-
able.[75] The aim of this statement is to offer
practical guidance to enable primary care or spe-
cialist physicians to intensify insulin therapy using
BIAsp 30. According to the statement, physic-
ians should consider intensifying basal insulin to
twice-daily BIAsp 30 if HbA1c is >8.0%, or if
HbA1c is between 7% and 8% and FPG is opti-
mized. If a patient on once- or twice-daily BIAsp 30
has within-target FPG but an HbA1c >7%, a
switch to twice- or three-times daily BIAsp 30
1508 Liebl et al.
Adis ª 2012 Liebl et al., publisher and licensee Springer International Publishing AG. Drugs 2012; 72 (11)
should be considered. If their FPG is above tar-
get, the dose should be titrated to achieve FPG
4–6mmol/L (72–108mg/dL); however, if hypo-
glycaemia occurs, an additional daily dose should
be added rather than further dose titration.
4.8 Antibodies
The development of antibodies against insulin
is common in individuals with diabetes who are
administering exogenous insulin; however, their
clinical relevance is debatable. Antibody responses
to IAsp (n = 1534) and human insulin (n = 886)
were investigated in four multinational, open stud-
ies of up to 1 year in duration.[76] In all four studies,
cross-reactive antibodies increased in patients
exposed to IAsp, with a maximum at 3 months,
after which there was a decrease toward baseline
levels at 9–12 months. No consistent relationship
between antibody formation and glycaemic con-
trol or adverse events was observed. Similar re-
sults were reported by Chen et al.[77] in 23 patients
with type 1 diabetes treated with BIAsp 30 for
12 weeks. Comparing individuals with high and
medium concentrations of circulating insulin
antibodies, higher levels of total but not free in-
sulin were observed in those with high antibody
concentrations; however, no difference in glycaemic
control was observed.
5. Clinical Evidence Translating to
Clinical Practice
A number of large, prospective, observational
studies observing the effects of initiating, switching
to or intensifying with BIAsp 30 have been con-
ducted.While randomized controlled trials (RCTs)
are rightly seen as the ‘gold standard’ for pro-
viding an evidence-based approach to medicine,
observational studies have an important and com-
plementary role. Prospective observational studies
can recruit larger patient cohorts, which means
they can be useful in predicting rare adverse events
that might be missed in smaller studies.[78] In
addition, patient demographics and treatment in
observational studies more closely reflect ‘real-life’
clinical practice than the more tightly controlled
RCT setting. Thismeans that observational studies
can be useful to corroborate results from RCTs
under more typical therapeutic conditions.[78,79]
However, observational studies are more open to
bias and confounding than RCTs as they reflect
clinical practice and lack randomization as well as
placebo or comparator treatment arms.
5.1 IMPROVE: Analysing BIAsp 30 Safety and
Efficacy in ‘Real-life’ Clinical Practice
IMPROVE was a 26-week observational
trial that included 51 430 individuals with type 2
diabetes across 11 countries (China, India, Japan,
Poland, Italy, Canada, Russia, Greece, Iran, Gulf
region and South Korea), of which data from
eight countries have been published.[80] Individuals
were enrolled into three study groups depending
on their previous diabetes treatment: no previous
pharmaceutical therapy, OADs only, and patients
prescribed insulin with or without OADs. HbA1c,
PPG and FPG levels, as well as the rate of hypo-
glycaemia, were measured in all three subsets of
patients at baseline and after 26 weeks after initia-
tion with/change to BIAsp 30 (table IV).[68,81-83]
Major hypoglycaemia was significantly reduced
in all patient subsets (no pharmaceutical therapy:
0.029 [baseline] to 0.002 events per patient-year;
OADs only: 0.071 [baseline] to 0.006 events per
patient-year; insulin–OADs: 0.269 [baseline] to
0.021 events per patient-year).[81]
5.2 PRESENT: Examining BIAsp 30 Safety and
Efficacy in 15 Countries Over 6 Months
PRESENT (Physicians’ Routine Evaluation
of Safety & Efficacy of NovoMix 30 Therapy)
was a 6-month observational study of 31 044 in-
dividuals with type 2 diabetes across 15 countries
initiating or switching diabetes treatment to
BIAsp 30 (with or without OADs). The key results
are summarized in table V.[84-88] In one subanalysis
of this trial, subjects were enrolled into differ-
ent subgroups depending on age, BMI or ethnic
background.[89] From data collected this way, it
was seen that age and BMI did not affect the
HbA1c-lowering qualities or the safety of BIAsp 30.
Ethnic origin, on the other hand, did seem
to play a role in HbA1c levels, being highest for
Black individuals at baseline (11.6%) compared
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with Asian/Pacific Island (9.3%), Middle Eastern/
Arabic (9.6%) and White (9.6%) populations.
Rates of hypoglycaemia were much lower for the
Black than the White subjects at the beginning of
the trial (1.86 vs 7.81 events per patient-year, re-
spectively). Overall outcomes showed that HbA1c
was reduced by 1.81%, FPG was lowered by
3.74mmol/L (67.32mg/dL) and hypoglycaemia
decreased from 5.4 to 2.2 events per patient-year
with BIAsp 30 (all p < 0.001).[84]
5.3 Additional Studies: Further Analyses
of BIAsp 30 Safety and Efficacy
In amultinational study acrossAustria,Germany
and Switzerland, insulin-naive patients with type 2
diabetes were randomized to receive either insulin
analogue basal-bolus treatment or BIAsp 30.[90]
BIAsp 30 therapy lowered HbA1c to a similar
degree as insulin analogue basal-bolus regimens
(-1.23% and -1.56%, respectively) and both treat-
ments were associated with similar, low rates of
hypoglycaemia.[90]
In addition to the IMPROVE and
PRESENT studies, data from the A1chieve
study, the largest ever observational study of in-
sulin use in type 2 diabetes, is now available. The
A1chieve study has been performed across 30
countries and is examining the safety and efficacy
of BIAsp 30, insulin detemir and IAsp treatment
in over 60 000 individuals with type 2 dia-
betes.[91,92] Mean baseline HbA1c in A1chieve was
9.5%. At 6 months, HbA1c had improved by 2.1%
in the entire cohort, 2.2% for prior non-insulin
users and 1.8% for prior insulin users. Results
achieved by BIAsp 30, insulin detemir and IAsp
were similar and did not depend on prior insulin
use. Hypoglycaemia did not increase in those in-
itiating insulin, and was reduced in those switching
insulin. There was no significant change in body-
weight, while lipid profile and systolic blood pres-
sure were improved.[92]
5.4 Country-Specific Populations and
Subgroup Analyses
A number of observational studies, or subgroup
analyses of larger multinational observational
studies, have examined the safety and efficacy of
BIAsp 30 in country-specific populations. The
Chinese, Indian, Iranian, Italian andKorean cohorts
of the IMPROVE and PRESENT studies have
been published.[93-100] These subgroup analyses
of large multinational observational studies are a
useful resource by providing a way to benchmark
local outcomes against those achieved globally.
Table IV. Results from the IMPROVE studya
Study Patient subset analysed Endpoint summary
Valensi et al.,[81] 2009 Global cohort of 52 419 individuals
(insulin-naive/prior insulin use) who
initiated or switched to BIAsp 30
No previous pharmaceutical therapy: -3.1% HbA1c, -5.9mmol/L
FPG and -9.0mmol/L PPG
OADs only: -2.1% HbA1c, -4.1mmol/L FPG and -6.1mmol/L PPG
Insulin –OADs: -2.0% HbA1c, -3.3mmol/L FPG and -5.1mmol/L
PPG
Major hypoglycaemia reduced by 94% (from a low baseline rate)
after BIAsp 30 initiation/switch for all groups
Yang et al.,[68] 2009 Global cohort of 29 160 insulin-naive
individuals, inadequately controlled with
OADs who initiated BIAsp 30
-2.1% HbA1c with BIAsp 30 (p <0.001)
-4.1mmol/L FPG with BIAsp 30 (p < 0.001)
39.2% of pts achieved HbA1c <7.0% without hypoglycaemia
Gumprecht et al.,[82]
2009
748 individuals previously treated with
basal insulin who switched to BIAsp 30
Major hypoglycaemia decreased with BIAsp 30 from 0.171 to 0.011
events/pt-y
33.8% of pts achieved HbA1c <7.0% without hypoglycaemia
Shah et al.,[8] 2009 3856 individuals who switched from BHIs to
BIAsp 30
30% of subjects achieved HbA1c <7.0% without hypoglycaemia
-0.84% HbA1c (p< 0.001)
a To convert mmol/L to mg/dL, multiply by 18.
BHI = biphasic human insulin; BIAsp = biphasic insulin aspart; FPG = fasting plasma glucose; HbA1c= glycated haemoglobin; OAD =oral
antidiabetic drug; PPG =postprandial glucose; pt(s) = patient(s); pt-y = patient-year.
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Similarly, smaller single-country observational
studies examining the initiation of BIAsp 30, such
as those carried out in the UK and Denmark,
provide physicians with clinically relevant in-
formation for the type of patients that they see in
daily practice.[101,102]
5.5 Retrospective Database Studies
In one retrospective database study that included
data from 7720 patients from over 350 UK general
practices, BIAsp 30 demonstrated significantly
greater HbA1c reductions versus BHI 30 in insulin-
naive type 1 patients (0.57%; p= 0.045), insulin-naive
patients with type 2 diabetes (0.17%; p = 0.003)
and insulin-experienced patients with type 2 dia-
betes (0.23%; p= 0.007).[102] The incidence rate
ratio for hypoglycaemia was significantly reduced
in insulin-naive patients with type 2 diabetes
(0.74; 95% CI 0.62, 0.89; p = 0.001) but not for
other groups. Logistic regression analysis ad-
justing for baseline HbA1c, age, sex and insulin
status demonstrated a significantly reduced risk
of experiencing a hypoglycaemic event in patients
with type 2 diabetes (OR = 0.718; 95% CI 0.593,
0.868; p = 0.001) but not in type 1 diabetes.
5.6 Devices
Insulin pens offer more convenience than vial
insulin because they are easier to use, more por-
table and allow the rapid selection of the correct
dose. By enabling more discrete injection, they
minimize potential embarrassment associatedwith
public injection,[103] giving individuals more life-
style flexibility. In addition, insulin pens offer a
more accurate way to inject insulin. This can be
particularly important for those patients with
vision impairment or manual dexterity issues and
can allow them to independently manage their
disease. By enabling more convenient, discrete and
accurate dosing of insulin, an insulin pen may im-
prove patients’ adherence to treatment and allow
them to more successfully manage their diabetes.
In a randomized, open-label, crossover study,
121 insulin-experienced patients with type 1 or
Table V. Results from the PRESENT studya
Study Patient subset analysed Endpoint summary
Khutsoane et al.,[84]
2008
Global cohort of 21 977 individuals (insulin-naive
or prior insulin use) who initiated or switched to
BIAsp 30
-1.81% HbA1c for all pts studied (p< 0.001)
Rate of total hypoglycaemia 5.4 events/pt-y at baseline and
2.2 events/pt-y at study end (p < 0.001)
Sharma et al.,[85] 2008 Global cohort of 21 977 individuals (insulin-naive
or prior insulin use) who initiated or switched to
BIAsp 30
Insulin-naive <5 y: HbA1c -2.21%
Insulin-naive ‡20 y: HbA1c -2.27%
Prior insulin <5 y: HbA1c -1.57%
Prior insulin ‡20 y: HbA1c -1.45%
All p < 0.05
Gu¨ler et al.,[86] 2009 8151 insulin-naive individuals who initiated with
BIAsp 30
BIAsp 30 only: HbA1c -2.12%; FPG -4.82mmol/L;
PPG -6.89mmol/L
BIAsp 30+ basal insulin: HbA1c -2.24%; FPG -4.48mmol/L;
PPG -6.66mmol/L
BIAsp 30+ basal insulin + sulphonylurea: HbA1c -1.78%;
FPG -3.57mmol/L; PPG -5.89mmol/L
Jang et al.,[87] 2008 3762 individuals previously on long- or
intermediate-acting human insulin (n =3414)
or long-acting insulin analogues (n = 348) who
switched to BIAsp 30
Previous human insulin: -1.42% HbA1c; –3.8 hypoglycaemic
events/pt-y
Previous insulin analogue treatment: HbA1c -1.60%; no
significant difference in hypoglycaemic events/pt-y
Shestakova et al.,[88]
2007
3985 individuals who switched from BHI to
BIAsp 30
HbA1c -1.58% after switching to BIAsp 30
FPG -2.92mmol/L upon change to BIAsp 30
4.6% fewer major hypoglycaemic episodes with BIAsp 30
a To convert mmol/L to mg/dL, multiply by 18.
BHI = biphasic human insulin; BIAsp = biphasic insulin aspart; FPG = fasting plasma glucose; HbA1c =glycated haemoglobin; PPG =
postprandial glucose; pt(s) =patient(s); pt-y =patient-year.
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type 2 diabetes were transferred to BIAsp 30.[103]
Following 4-week dose optimizationwith BIAsp 30
using their usual type of syringe, patients were
randomized to a prefilled disposable pen (FlexPen
[FP]) or vial and syringe for 4 weeks, after which
they switched to the other administration device
for the final 4 weeks.[103] A higher percentage of
patients preferred the FP (74%): they felt it was
more discrete for public use (85%), found it easier
to use (74%) and found the dosing scale easier
to read (85%) than the vial and syringe.[103] The
Next Generation FlexPen (NGFP) was laun-
ched in 2009 and was demonstrated to be at least
as accurate as the FP, required less injection force
and was judged by patients to be more comfor-
table and easier to use than the FP.[104] In another
study, a total of 64 individuals with type 1 or type
2 diabetes were asked to compare the FP with
the NGFP for visual appearance, ease of needle
attachment, ease of use, convenience, trust and
safety.[105] The majority of patients found it easier
to identify the correct insulin analogue with
the NGFP; attaching the NovoTwist needle to the
NGFP was significantly easier than attaching the
NovoFine needle to the FP; the NGFPwas easier
to use; and a slight majority (52%) had more trust
and confidence in the NGFP than in the FP.[105]
Overall, 95% of patients preferred the NGFP and
77% preferred the NovoTwist needle.[105]
6. Newer Concepts of Practice
6.1 Cost Effectiveness (Health Economics)
Cost-effectiveness assessments of treatments
for diabetes ideally take into account both the
direct and the indirect costs of treatment and
complications and should relate these costs to the
clinical benefits associated with treatment (table
S2 in the SDC). Costs include the direct acquisi-
tion cost of the drug, medical costs associated
with scheduled physician visits, costs due to acute
adverse events such as hypoglycaemia, the costs
of treating long-term diabetic complications and
lost productivity.
The studies reviewed utilized the Center for
Outcomes Research (CORE) diabetes model,
which is a validated computer simulation that
projects long-term health outcomes and economic
consequences of different treatments by assessing
the likelihood of patients developing complica-
tions such as cardiovascular disease, eye disease,
hypoglycaemia, nephropathy and renal failure,
neuropathy, foot ulcer, amputation, stroke, keto-
acidosis, lactic acidosis and mortality; as well as
costs of adverse events like hypoglycaemia.[106]
Given country-specific differences in medical
practice and costs, it is difficult to extrapolate
data from one country to predict cost effectiveness
in another. In this respect, use of country-specific
cohorts, costs, utility data, information on med-
ical practices as well as clinical probability data
where available, combined with data from large,
well run observational trials can provide impor-
tant input on which to base finely tuned, country-
specific, health economic analyses.
The cost-effectiveness comparisons with insu-
lin glargine included in this review[107-110] all uti-
lized data from the 28-week INITIATE trial[31]
to provide baseline characteristics and treatment
outcomes for the simulated cohorts. Modelling
in Palmer et al.[109] also utilized data from the
OnceMix study.[47] These simulated cohorts were
then used to model long-term cost effectiveness
over a 35-year period. The INITIATE study
demonstrated that BIAsp 30 plus OADs lowered
HbA1c to a greater extent than the same oral com-
bination with insulin glargine (-2.79 vs -2.36%,
respectively), but with a higher daily insulin dose
(+0.82 vs +0.52 units/kg, respectively), change in
bodyweight (+5.4 vs +3.5 kg, respectively) and
minor hypoglycaemia (3.4 vs 0.7 episodes per
patient-year, respectively).[31] Costs were mod-
elled in the US, Chinese, Swedish and UK set-
tings using local pharmacy and hospital costs.
The total cost in each treatment arm included
direct medical resource costs plus the costs of
treating complications. Therefore, if the CORE
model predicted that treatment A would reduce
the frequency, or delay the onset, of diabetic com-
plications versus treatment B, then the total cost
of treatment A may be less than treatment B
(despite higher medical resource costs). On this
basis, theCOREmodel demonstrated that BIAsp 30
was dominant (e.g. BIAsp 30 was more effective
and the total lifetime treatment costs were lower)
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in China and Sweden (table VI).[109,110] BIAsp 30
was shown to be cost effective (e.g. the total life-
time costs of treatment were higher with BIAsp 30,
but the additional costs were in the range deemed
to be acceptable value for money in the respective
countries for the efficacy benefits gained) in the
US and the UK (table VI).[107,108]
Three published analyses have examined the
cost effectiveness of BIAsp 30 compared with
BHI using the Saudi Arabian and South Korean
cohorts of PRESENT to model costs in those
countries and theCanadian cohort of IMPROVE
to model US costs.[111-113] BIAsp 30 was demon-
strated to be dominant over BHI 30 in the Saudi
Arabian setting and was cost effective in the South
Korean and US settings (table VII).
6.2 Quality of Life and Treatment Satisfaction
Treatment satisfaction can positively impact
patient compliance, cost of care and self-
management behaviour.[114] Treatment satisfaction
was examined in 233 individuals recruited to the
INITIATE trial, which compared twice-daily
BIAsp 30 and once-daily insulin glargine.[114] Neuro-
pathy and the number of hypoglycaemic events
during the day significantly negatively impacted
treatment satisfaction while treatment efficacy
significantly improved treatment satisfaction.[114]
However, there was no significant relationship
between the number ofminor hypoglycaemic events,
weight gain or treatments with one versus two daily
injections with overall treatment satisfaction.[114]
Table VI. Cost effectiveness of biphasic insulin aspart 30 compared with insulin glarginea
Study Clinical data source Country setting
HE model, time horizon
Study endpoint summary
BIAsp 30 cost effective vs GLA in a US setting
Ray et al.,[107] 2007 INITIATE
28wk RCT





ICER $46 533 per QALY gained with BIAsp 30
Lifetime cost per pt treated successfully to target
HbA1c <7.0% was $US80 523 lower with BIAsp 30
BIAsp 30 dominant vs GLA in a Chinese setting






BIAsp 30 od increased LE by 0.04 y
Reduced direct medical costs by CNY59 710
per pt ($US9271)
BIAsp 30 bid increased LE by 0.08 y
Reduced direct medical costs by CNY107 349 per pt
($US16 669)
BIAsp 30 dominant vs GLA in a Swedish setting
Goodall et al.,[110] 2008 INITIATE
28wk RCT




diabetes model, 35 y
Improvement in QALE of 0.21 y
Reduced total lifetime costs of SEK10367
($US1594) per pt
BIAsp 30 cost effective vs GLA in a UK setting
Valentine et al.,[108] 2005 INITIATE
28wk RCT





BIAsp 30 improved discounted LE (0.19 – 0.20 y)
QALE improved 0.19 – 0.14 QALYs
Reduced incidence of retinopathy and nephropathy
Total lifetime direct costs £1319 higher with BIAsp 30
than glargine
ICER £6951 ($US11 413) per QALY gained
a $US costs reflect currency exchange rates in August 2011.
BIAsp =biphasic insulin aspart; bid = twice daily; CORE =Center for Outcomes Research; CNY =Chinese Yuan; GLA = insulin glargine;
HbA1c=glycated haemoglobin; HE =health economics; ICER = incremental cost-effectiveness ratio; LE = life expectancy; od =once daily;
pt = patient; QALE =quality-adjusted life-expectancy; QALY = quality-adjusted life-year; RCT = randomized controlled trial; SEK =Swedish
Krona; tid = three-times daily; T2DM = type 2 diabetes mellitus.
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In a larger sample of 17 488 patients from the
IMPROVE study, switching from prior OAD
therapy to BIAsp 30 was associated with signif-
icantly improved treatment satisfaction based on
the DiabMedSat testing of Overall, Treatment
Burden, Symptoms and Efficacy, and Treatment
Satisfaction (p < 0.001).[115] In a regression anal-
ysis, achieving target HbA1c levels was associ-
ated with greater satisfaction in the Symptoms
and Treatment Burden domains, while weight gain
and experiencing minor hypoglycaemic events
were negatively associated with Treatment Sa-
tisfaction.[115] Similar results were reported in the
study of treatment satisfaction of patients in the
Indian cohort (n = 349) of IMPROVE, with sig-
nificant improvements in overall treatment satis-
faction and the domains such as burden, symptoms
and efficacy (p< 0.001).[116] Interestingly, analysis
of the Japanese IMPROVE cohort demonstrated
significant improvements in burden (p < 0.041),
efficacy (p < 0.001) and symptoms (p < 0.049) fol-
lowing the switch from prior OAD to BIAsp 30
treatment, but overall treatment satisfaction was
similar (p < 0.079).[117]
7. Where is BIAsp 30 Heading?
The prevalence of diabetes continues to rise
globally, reflecting changing lifestyles and the
increasing prevalence of obesity. The impact of
diabetes on healthcare costs is high and will
continue to increase. Given the increasing num-
bers of patients and limited healthcare resources,
it is likely that there will be an increasing need for
patients to be treated in a primary care rather
than in a specialist setting, and there will be greater
emphasis on patients self-managing their disease.
In this context, premix insulins, such as BIAsp 30,
provide a useful option as they offer the simpli-
city and convenience of being able to control both
fasting and prandial glucose with a single injec-
tion. In addition, a simple dose-titration algo-
rithm means that patients can adjust their daily
dosing without the need to consult their health-
Table VII. Cost effectiveness of biphasic insulin aspart 30 vs human insulina
Study Clinical data source Country setting
HE model, time horizon
Study endpoint summary
BIAsp 30 cost effective vs BHI in a South Korean setting




BIAsp 30 vs BHI
T2DM (n= 1321)
South Korea, CORE
Diabetes model, 30 y
Discounted mean QALE increased by 0.30 QALYs
Mean increase in direct costs of KRW1777 323 ($US1673)
BIAsp 30 associated with ICER of KRW5916 758 ($US5572)
per QALY gained











BIAsp 30 improved LE by 0.202 y
QALE improved by 0.301 QALYs
Reduced incidence of most diabetes-related complications
Increased lifetime direct medical costs ($US76 517 vs $US67 518)
with BIAsp 30
ICER $US29 870 per QALY gained
BIAsp 30 cost effective vs BHI in a Saudi Arabian setting
Ali et al.,[113] 2008 Saudi Arabian
PRESENT cohort
26wk obs study
BIAsp 30 vs BHI
T2DM (n= 598)
Saudi Arabia, CORE
Diabetes model, 40 y
BIAsp 30 increased LE by 0.62 y
QALE increased by 0.96 QALYs
Direct medical cost savings of SAR53 879 ($US14 367) per pt
Cost savings reflected lower costs of hypoglycaemia and renal
complications
a $US costs reflect currency exchange rates in August 2011.
BHI = biphasic human insulin;BIAsp = biphasic insulin aspart;CORE =Center for Outcomes Research; ICER = incremental cost-effectiveness
ratio; KRW =South Korean Won; LE = life expectancy; obs =observational; pt = patient; QALE = quality-adjusted life-expectancy; QALY =
quality-adjusted life-year; SAR =Saudi Arabian Riyals; T2DM = type 2 diabetes mellitus.
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care provider. The ability of patients to self-
monitor and self-adjust their BIAsp 30 regimen
was demonstrated by a study of 149 patients with
type 2 diabetes who initiated BIAsp 30 after
failing on OADs or existing insulin regimens.[118]
Patients were trained to self-monitor and adjust
their BIAsp 30 over a maximum of 10 weeks. Dia-
betes nurses were consulted by telephone after
each weekly series of blood glucose measurements
until the patient was confident in self-adjusting
their insulin doses. Self-adjusted BIAsp 30 re-
sulted in significant reductions in mean HbA1c
(1.9%), mean FPG (2.8mmol/L) and mean PPG
(2.9mmol/L) [p= 0.001]. Additionally, 91% and
52% of patients achieved HbA1c <7% and £6.5%,
respectively. No major or nocturnal hypoglycaemic
episodes were reported, although 15% of patients
reported minor hypoglycaemia. Similar results,
supporting the ability of patients to self-titrate
BIAsp 30, were reported in a large study of al-
most 5000 patients in a primary care setting.[119]
These results showed HbA1c reductions of ap-
proximately 2.5% to around 7.5% in three groups
of patients randomized to self-titration of BIAsp 30
with no dietary counselling, or one or three dietary
counselling sessions conducted by telephone.[119]
Premix insulins also offer a simple route to
insulin intensification as further mealtime doses
can be up to three times daily, which means that
patients can stick with a familiar insulin even as
their diabetes progresses. Only once their dia-
betes is no longer controlled by three times daily
premix would patients and their healthcare pro-
viders need to consider a move to a more com-
plicated basal-bolus regimen.
There are currently two ongoing RCTs and
one planned RCT that will provide additional
clinical insights into BIAsp 30. The EasyMix
trial (BIAsp 3756) was conducted in insulin-naive
Chinese and Japanese subjects with type 2 dia-
betes. It assessed BIAsp 30 and insulin glargine
(both once daily) in combination with metformin
and glimepiride. The results from the EasyMix
trial will shortly be available at ClinicalTrials.gov.
The SimpleMix trial (BIAsp 3878) recruited
subjects between September and December 2011
with the primary aim of demonstrating that subject-
driven titration is non-inferior to investigator-driven
titration of BIAsp 30 in type 2 diabetes inadequately
controlled on basal insulin analogues. In addition, a
new BIAsp 30 RCT (BIAsp 3963) is recruiting
patients as of June 2012 and will examine combi-
nation therapy with BIAsp 30 and sitagliptin.
8. Discussion
As it enters its 10th year on the international
market, BIAsp 30 is a time-tested molecule that
has demonstrated a positive efficacy and safety
profile, having been used by millions of diabetes
patients worldwide. In addition, BIAsp 30 is sup-
ported by an extensive selection of efficacy and
safety data ranging from multinational RCTs to
observational data from large international obser-
vational studies, including data from A1chieve,
the largest observational study of insulin use in
type 2 diabetes, which includes over 60 000 pa-
tients.[91,92] By combining rapid- and intermediate-
acting insulins in a single formulation, BIAsp 30
offers a simple and convenient way to provide
coverage of both FPG and PPG. Administered
once or twice daily, BIAsp 30 is a useful option
for individuals initiating insulin. BIAsp 30 can be
intensified up to three times daily with meals,
giving options for treatment intensification as an
individual’s diabetes progresses. Given the benefits
of BIAsp 30 over BHI 30 – including the conveni-
ence of being able to inject immediately before or
following a meal, improved PPG control and re-
ducedmajor and nocturnal hypoglycaemia –most
patients on BHI 30 may benefit from a switch to
BIAsp 30. It has become increasingly clear that
hypoglycaemic episodes, whether major or minor,
have a detrimental effect on the lives of in-
dividuals with diabetes as well as their families; re-
sult in lost productivity; and have both acute, and
potentially longer-term, adverse health impacts.
Therefore, treatments such as BIAsp 30 or other
premixed insulin analogues such as biphasic in-
sulin lispro 25, which offer the potential to reduce
the risk of hypoglycaemic episodes, can have
important benefits for patients. BIAsp 30 also
provides a simple way to intensify from basal in-
sulin if PPG coverage is required, which can be
useful in those patients who have concerns about
the complexity of basal-bolus options. BIAsp 30
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has been shown to be a cost-effective or dominant
(cost-saving and more effective than the com-
parator) treatment option in a number of coun-
tries, and studies have demonstrated significantly
improved quality of life for patients switching
fromOADs to BIAsp 30. In conclusion, BIAsp 30
offers a simple, flexible option with a positive
safety profile for insulin initiation and intensifica-
tion that provides coverage of FPG and PPG.
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